EGFR and neoplasm: The response rate to gefitinib and erlotinib in patients with tumors exhibiting activating mutations of EGFR is approximately 75%, suggesting that these mutations, at least in part, may have caused malignant transformation and contribute in large to the tumor maintenance pathway [16, 17].